Show simple item record

dc.contributor.authorNowakowski, GS
dc.contributor.authorWillenbacher, W
dc.contributor.authorGreil, R
dc.contributor.authorLarsen, TS
dc.contributor.authorPatel, K
dc.contributor.authorJäger, U
dc.contributor.authorManges, RF
dc.contributor.authorTrümper, L
dc.contributor.authorEveraus, H
dc.contributor.authorKalakonda, N
dc.contributor.authorBrown, P
dc.contributor.authorJørgensen, JM
dc.contributor.authorCunningham, D
dc.contributor.authorDell'Aringa, J
dc.contributor.authorFox, B
dc.contributor.authorRubio, ND
dc.contributor.authorKilavuz, N
dc.contributor.authorCasadebaig, M-L
dc.contributor.authorManzke, O
dc.contributor.authorMunoz, J
dc.date.accessioned2022-02-11T09:53:51Z
dc.date.available2022-02-11T09:53:51Z
dc.date.issued2021-11-19
dc.identifier.citationInternational journal of hematology, 2021en_US
dc.identifier.issn0925-5710
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5009
dc.identifier.eissn1865-3774en_US
dc.identifier.eissn1865-3774
dc.identifier.doi10.1007/s12185-021-03241-4en_US
dc.identifier.doi10.1007/s12185-021-03241-4
dc.description.abstractPatients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can increase antitumor efficacy. This study investigated durvalumab, a programmed death-ligand 1 inhibitor, combined with R-CHOP or lenalidomide + R-CHOP (R<sup>2</sup>-CHOP) in newly diagnosed high-risk DLBCL. Patients received durvalumab 1125 mg every 21 days for 2-8 cycles + R-CHOP (non-activated B-cell [ABC] subtype) or R<sup>2</sup>-CHOP (ABC), then durvalumab consolidation (1500 mg every 28 days). Of 46 patients, 43 received R-CHOP and three R<sup>2</sup>-CHOP. All patients had the high-risk disease; 14 (30.4%) and eight (17.4%) had double- or triple-hit DLBCL, respectively. Following induction, 20/37 (54.1%) patients receiving durvalumab + R-CHOP achieved complete response (CR), and seven (18.9%) partial response (PR); 25 (67.6% [95% CI 50.2-82.0]) continued to consolidation and were progression-free at 12 months. Among efficacy-evaluable patients with double- or triple-hit DLBCL (n = 12), five achieved CR and five PR. Adverse events were generally consistent with R-CHOP. Correlative analyses did not identify conclusive biomarkers of response. Durvalumab + R-CHOP is feasible in DLBCL with no new safety signals, but the combination provided no greater benefit than R-CHOP.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.titleSafety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-10-17
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1007/s12185-021-03241-4en_US
rioxxterms.licenseref.startdate2021-11-19
dc.relation.isPartOfInternational journal of hematologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine (RMH Smith Cunningham)
dc.contributor.icrauthorCunningham, Daviden_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record